By Denny Jacob
Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.
The medical technology company said the regulator approved BrainSense Adaptive deep brain stimulation and BrainSense Electrode Identifier. It added that they offer therapy personalization for symptom control that automatically adjusts to a patient's needs.
Medtronic said both BrainSense offerings are available in Europe. Patient programmings in the U.S. will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months, it added.
Parkinson's occurs when cells deep in the brain that produce dopamine, which coordinates movement, become impaired or die. Symptoms include tremors, stiffness, slow movements and problems with balance.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 24, 2025 09:28 ET (14:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。